Evidence map›Paper›PMID 42605169›Full record

ArticleBiotechnology journal2026

Impact of Cistron Topology and Bicistronic Vector Design in the piggyBac Transposon System for Improved Antibody Expression.

Jason Vitko, Thomas King, Efecan Aral, Steven McLellan, Hope Divello, Sara Maimouni, Tiffany McLamarrah, Jennifer Tedstone, Victor Cairns, Christine DeMaria and 1 more

Abstract read
In one paragraph

Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jason VitkoCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.ORCID https://orcid.org/0009-0006-9113-6705
Thomas KingCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.ORCID https://orcid.org/0009-0002-5918-2710
Efecan AralCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.ORCID https://orcid.org/0000-0002-2039-5041
Steven McLellanCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.ORCID https://orcid.org/0009-0005-0784-4825
Hope DivelloCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.ORCID https://orcid.org/0009-0008-6365-4278
Sara MaimouniCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.
Tiffany McLamarrahCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.ORCID https://orcid.org/0009-0005-1294-0731
Jennifer TedstoneCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.
Victor CairnsCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.
Christine DeMariaCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.
John J ScarcelliCell Line Development, Global Chemistry, Manufacturing & Controls, Sanofi Corporation, Framingham, Massachusetts, USA.

Funding

Sanofi
6 · The paper itself

Abstract

The use of transposon-based technologies in cell line development has gained significant traction over the past decade. This study investigates the piggyBac transposon system combined with bicistronic vectors for monoclonal antibody expression, helping address the complex demands of multi-specific antibody formats that require multiple cistrons. We systematically evaluated bicistronic vector modifications within the piggyBac framework, including promoter sequences, reporter placements, and cassette configurations, and compared performance to piggyBac/single-gene vector co-transfection methods. Our findings demonstrate that double human CMV promoter configurations driving both heavy and light chain genes significantly enhanced pool productivity (2 to 2.5-fold) and reporter expression compared to separate promoter designs. Among tested cassette arrangements, the Light chain-GS-Heavy chain configuration yielded optimal productivity (1.5 to 6-fold) and superior heavy chain/light chain RNA transcript ratios (1.4 to 3.8-fold and 1.3 to 6.1-fold, respectively). While unfed batch conditions showed comparable productivities between optimized piggyBac/bicistronic and piggyBac/single-gene systems, the bicistronic approach exhibited superior productivity performance under fed-batch conditions (1.5-fold), with the resulting clones demonstrating significantly high productivity (top clone 9.6 g/L). This represents the first reported use of LC-selection marker-HC topology for monoclonal antibody expression, establishing a foundation for improved therapeutic biologic production through multicistronic vector systems combined with the piggyBac transposon strategy.

Indexed as

Antibodies, MonoclonalDNA Transposable ElementsGenetic VectorsAnimalsCHO CellsCricetulusHumansPromoter Regions, GeneticTransfectionAntibodies, MonoclonalDNA Transposable Elementsantibody productivity optimizationbicistronic vectorsenhancer/promoter designpiggyBac transposonvector topology design

Identifiers

PMID42605169
PMCPMC13478696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.